Q1 2025 Ascelia Pharma AB Earnings Call Transcript
Key Points
- Ascelia Pharma AB (FRA:7ZA) has advanced Orviglance to the registration phase, preparing for NDA submission to the FDA by early August 2025.
- The company has completed clinical development for Orviglance with nine studies, including strong Phase 3 results showing superiority in liver lesion visualization.
- Orviglance addresses a significant unmet need for liver imaging in cancer patients with impaired kidney function, targeting an $800 million annual market.
- Successful warrant exercise in April 2025 raised SEK43 million, extending the cash runway to at least the end of the year.
- Positive feedback from the FDA meeting in Q1 2025 supports the planned NDA submission, indicating a clear path forward for approval.
- The financial runway only extends to the end of 2025, creating pressure to secure a commercialization partnership or alternative financing.
- There are potential risks associated with the NDA submission process, including unforeseen challenges or questions from the FDA.
- The company is still in the process of securing a commercialization partner, which could impact the timing and success of Orviglance's market launch.
- Dependence on external partners for commercialization could affect revenue sharing and control over the product's market strategy.
- The timeline for NDA submission has been extended to early August 2025, which may delay potential market entry and revenue generation.
Good morning, everybody, and welcome to today's event with Ascelia Pharma. With me today, I have the Deputy CEO and CFO, Julie Brogren. And the focus for today's event is, of course, the recently published Q1 report, it came out Friday; and also focus on events after closing of the quarter. And as always, we will record this event and both, HCA Capital and Ascelia Pharma will publish the event after editing later today. If you have any questions, then please post them just below the video window here and I will forward them to Julie when she have done her presentation. So welcome everybody and let's start. Julie, welcome.
Thank you, [Klaus]. It is good to be here and give you an update on our Q1. I'll, of course, do just a quick overview at Ascelia. It includes some forward-looking statements, so please pay attention to this.
Just the highlights of Ascelia. We are based in Malmo. Listed on Nasdaq in Stockholm. We have two assets
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
